Clinical trial
A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
NCT01672736 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- University Health Network, Toronto
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 30, 2012
- Completion date
- December 27, 2017
- Enrollment
- 19 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.